| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $937,839 ) |
| | 2024 | 2024 | OMNIOX INC | 181 2ND ST | SAN FRANCISCO | CA | 94105-3808 | SAN FRANCISCO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 001 | 6 | NIH | 8/11/2024 | $995,592 |
| | 2024 | 2022 | OMNIOX INC | 181 2ND ST | SAN FRANCISCO | CA | 94105-3808 | SAN FRANCISCO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 000 | 6 | NIH | 2/1/2024 | -$57,753 |
| | 2024 | 2020 | OMNIOX INC | 181 2ND ST | SAN FRANCISCO | CA | 94105-3808 | SAN FRANCISCO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 000 | 4 | NIH | 1/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $999,580 ) |
| | 2023 | 2023 | OMNIOX INC | 181 2ND ST | SAN FRANCISCO | CA | 94105-3808 | SAN FRANCISCO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 000 | 5 | NIH | 8/29/2023 | $999,580 |
|
| Issue Date FY: 2022 ( Subtotal = $522,676 ) |
| | 2022 | 2022 | OMNIOX, INC. | 181 2ND ST | SAN FRANCISCO | CA | 94105-3808 | SAN FRANCISCO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 001 | 6 | NIH | 4/12/2022 | $522,676 |
| | 2022 | 2021 | OMNIOX, INC. | 181 2ND ST | SAN FRANCISCO | CA | 94105-3808 | SAN FRANCISCO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 000 | 5 | NIH | 3/2/2022 | $0 |
| | 2022 | 2017 | OMNIOX, INC. | 181 2ND ST | SAN FRANCISCO | CA | 94105-3808 | SAN FRANCISCO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 000 | 3 | NIH | 8/17/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $538,027 ) |
| | 2021 | 2021 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 001 | 5 | NIH | 6/24/2021 | $0 |
| | 2021 | 2021 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 000 | 5 | NIH | 5/14/2021 | $538,027 |
| | 2021 | 2020 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 000 | 4 | NIH | 5/20/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $232,831 ) |
| | 2020 | 2020 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 001 | 4 | NIH | 8/18/2020 | $232,127 |
| | 2020 | 2020 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 000 | 4 | NIH | 4/16/2020 | $704 |
| | 2020 | 2019 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 000 | 3 | NIH | 7/16/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,228,367 ) |
| | 2019 | 2019 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 001 | 3 | NIH | 8/8/2019 | $0 |
| | 2019 | 2019 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 003 | 3 | NIH | 9/5/2019 | $681,601 |
| | 2019 | 2019 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 000 | 3 | NIH | 6/12/2019 | $546,766 |
| | 2019 | 2018 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 002 | 2 | NIH | 8/28/2019 | $12,990 |
| | 2019 | 2018 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 000 | 2 | NIH | 2/14/2019 | $0 |
| | 2019 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 000 | 3 | NIH | 10/30/2018 | $0 |
| | 2019 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 001 | 3 | NIH | 3/8/2019 | $0 |
| | 2019 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 002 | 3 | NIH | 5/9/2019 | $0 |
| | 2019 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 003 | 3 | NIH | 7/31/2019 | $0 |
| | 2019 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 001 | 1 | NIH | 8/28/2019 | -$12,990 |
|
| Issue Date FY: 2018 ( Subtotal = $1,617,845 ) |
| | 2018 | 2018 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 000 | 2 | NIH | 4/3/2018 | $585,583 |
| | 2018 | 2018 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 000 | 2 | NIH | 8/31/2018 | $1,032,262 |
| | 2018 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 000 | 3 | NIH | 9/5/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,110,263 ) |
| | 2017 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 000 | 3 | NIH | 7/25/2017 | $1,209,149 |
| | 2017 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R01CA204723 | Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier | 000 | 1 | NIH | 4/27/2017 | $602,718 |
| | 2017 | 2017 | OMNIOX, INC | 75 SHOREWAY RD STE B | SAN CARLOS | CA | 94070-2727 | SAN MATEO | USA | R44HD094414 | Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass | 000 | 1 | NIH | 8/2/2017 | $298,396 |
|
| Issue Date FY: 2016 ( Subtotal = $1,115,299 ) |
| | 2016 | 2016 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R44NS076272 | Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier | 000 | 2 | NIH | 7/28/2016 | $1,115,299 |
|
| Issue Date FY: 2015 ( Subtotal = $280,141 ) |
| | 2015 | 2015 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R43CA192765 | Chemosensitizing Hypoxic Multiple Myeloma With Tunable, Long-Lived Oxygen Carriers | 000 | 1 | NIH | 8/1/2015 | $280,141 |
|
| Issue Date FY: 2014 ( Subtotal = $1,225,000 ) |
| | 2014 | 2014 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R43CA177097 | Engineering of human H-NOX as an oxygen delivery therapeutic for prolonged admini | 000 | 1 | NIH | 9/19/2014 | $225,000 |
| | 2014 | 2014 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R44CA138006 | TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO | 000 | 7 | NIH | 8/27/2014 | $1,000,000 |
|
| Issue Date FY: 2013 ( Subtotal = $961,000 ) |
| | 2013 | 2013 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R44CA138006 | TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO | 000 | 6 | NIH | 9/17/2013 | $961,000 |
|
| Issue Date FY: 2012 ( Subtotal = $2,523,624 ) (Continued on the next page) |
| | 2012 | 2012 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R43NS076272 | REDUCING BRAIN INJURY AFTER FOCAL ISCHEMIA USING A NITRIC OXIDE-NEUTRAL OXYGEN CA | 000 | 1 | NIH | 7/3/2012 | $274,359 |
| | 2012 | 2012 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R44CA138006 | TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO | 001 | 5 | NIH | 9/26/2012 | $1,000,000 |
| | 2012 | 2012 | OMNIOX INC | 1010 HADDON DRIVE | SAN MATEO | CA | 94402 | SAN MATEO | USA | R44CA138006 | TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO | 000 | 4 | NIH | 3/15/2012 | $949,265 |
|
